Efficacy

Efficacy of Xpovio (Selinexor) in Treating Multiple Myeloma

Xpovio (selinexor) is a prescription medication that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma in adult patients. Selinexor works as a selective inhibitor of nuclear export, targeting a protein known as exportin 1 (XPO1). This action leads to the accumulation of tumor suppressor proteins in the cell nucleus, thereby restoring their ability to promote cancer cell death and reducing the proliferation of cancer cells. Clinical trials have demonstrated that Xpovio, particularly when combined with dexamethasone, is effective in treating patients with relapsed or refractory multiple myeloma who have received prior therapies.

The efficacy of Xpovio in the treatment of multiple myeloma was established through a pivotal phase 2b study known as STORM, which evaluated selinexor in combination with dexamethasone. The results showed a meaningful clinical response in a significant portion of patients who had previously been treated with multiple lines of therapy, including proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies. The overall response rate and duration of response were considered clinically beneficial for this heavily pretreated patient population.

Efficacy of Sarclisa (Isatuximab) in Treating Multiple Myeloma

Sarclisa (isatuximab) is another medication approved by the FDA for the treatment of multiple myeloma. Isatuximab is a monoclonal antibody that targets a specific protein found on the surface of multiple myeloma cells known as CD38. By binding to CD38, Sarclisa helps to induce programmed cell death and also triggers the immune system to attack the cancer cells. It is often used in combination with other medications, such as pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

The clinical efficacy of Sarclisa was demonstrated in a randomized, multicenter, open-label phase 3 trial known as ICARIA-MM. The study showed that patients treated with the combination of isatuximab, pomalidomide, and dexamethasone had a significantly longer progression-free survival compared to those who received only pomalidomide and dexamethasone. Additionally, the study reported a higher overall response rate in the Sarclisa combination group. These results indicate that Sarclisa, when used in combination with other therapies, provides a valuable treatment option for patients with relapsed or refractory multiple myeloma.